Join to view full profile
1665 Aurora CtAurora, CO 80045
Phone+1 720-848-0000
Dr. Kim is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
New York Presbyterian Hospital (Cornell Campus)Fellowship, Hematology and Medical Oncology, 2013 - 2016
NYU Grossman School of MedicineResidency, Internal Medicine, 2009 - 2012
Columbia University Vagelos College of Physicians and SurgeonsClass of 2009
Certifications & Licensure
CO State Medical License 2019 - 2027
DC State Medical License 2016 - 2020
MD State Medical License 2016 - 2020
NY State Medical License 2011 - 2016
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification MEDSEEK Empower, SymphonyCare, LLC, 2017
- CMS Meaningful Use Stage 1 Certification ARIA Oncology Information System (for Medical Oncology), Varian Medical Systems, 2017
Clinical Trials
- A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) Start of enrollment: 2022 Feb 23
Roles: Contact
Publications & Presentations
PubMed
- NCCN Guidelines® Insights: Esophageal and Esophagogastric Junction Cancers, Version 4.2026.Jaffer A Ajani, Thomas A D'Amico, David J Bentrem, Sakti Chakrabarti, Carlos U Corvera
Journal of the National Comprehensive Cancer Network. 2026-09-01 - 14 citationsA First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors.Geoffrey Ku, Lin Shen, Farshid Dayyani, Jeremy Kratz, Xinjun Liang
Clinical Cancer Research. 2025-12-01 - 5 citationsPhase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer.Robert W Lentz, Julie Lang, Todd M Pitts, Patrick Blatchford, Junxiao Hu
Cancer Research Communications. 2025-11-01
Press Mentions
Should PPIs Be Avoided in Patients with Gastric Cancer? What New Findings Mean for PracticeJanuary 23rd, 2026- Clinical Trial for Esophageal Cancer at CU Cancer Center Moves Treatment Forward for PatientsAugust 26th, 2024
- New Strategies and Platforms for Gastroesophageal CancerJune 24th, 2026
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
